Last reviewed · How we verify
NCT06929533: PGx-SUPPORT
Pharmacogenomics-Supported Psychotropic Prescribing Trial
NA trial testing Pharmacogenetic Testing in Mental Disorder in 200 participants. Currently enrolling.
31 December 2028
Quick facts
| Lead sponsor | University of Manitoba |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 200 |
| Start date | 1 July 2025 |
| Primary completion | 31 December 2028 |
| Estimated completion | 31 December 2030 |
| Sites | 2 locations across Canada |
Drugs / interventions tested
- Pharmacogenetic Testing
Conditions studied
- Mental Disorder — all drugs for Mental Disorder →
- Pharmacogenetics — all drugs for Pharmacogenetics →
- Adverse Drug Reaction (ADR) — all drugs for Adverse Drug Reaction (ADR) →
- Effectiveness — all drugs for Effectiveness →
Sponsor
University of Manitoba
Who can join
18 and older, any sex, with Mental Disorder or Pharmacogenetics. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Investigate the feasibility and utility of implementing pharmacogenetic testing for adults (aged 18 and older) seeking care for mental illness in Manitoba.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06929533
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pharmacogenetic Testing
Trials testing the same drug.
- NCT04797364 — Pharmacogenetic Supported Prescribing in Kids · NA · recruiting
- NCT04685304 — Pharmacogenomics Applied to Chronic Pain Treatment in Primary Care · NA · unknown
Other recruiting trials for Mental Disorder
Currently open trials in the same condition.
- NCT07010614 — Brain Stimulation to the Hippocampus in Schizophrenia · NA · recruiting
- NCT06813066 — Simulating Psychotherapeutic Sessions With Generative Artificial Intelligence · NA · active not recruiting
- NCT06376734 — Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness · Phase 2 · recruiting
- NCT06625437 — ACT for HIV-Positive Men · NA · recruiting
- NCT06702488 — Dexmedetomidine and Magnesium Sulfate in the Reduction Cognitive Dysfunction in Geriatrics · Phase 1 · recruiting
Other University of Manitoba trials
Trials by the same sponsor.
- NCT07528417 — Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX) · Phase 2 · not yet recruiting
- NCT07366515 — Feasibility of a Multimodal Virtual Reality Intervention to Reduce Preoperative Anxiety in Cancer Surgery Patients · NA · not yet recruiting
- NCT07354386 — Effects of Dried Whole Fruits on Metabolism in Diabetes · NA · enrolling by invitation
- NCT07361315 — Development and Online Evaluation of an Online Course for Parasomnias · NA · recruiting
- NCT07023744 — CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06929533 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Manitoba
- Last refreshed: 8 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06929533.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing